Cas:53332-29-9 DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT manufacturer & supplier

Chemical Name:DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT

CAS.NO:53332-29-9

Synonyms:EINECS 258-480-4

Molecular Formula:C₁₆H₁₈N₂O₆S

Molecular Weight:366.39

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like EINECS 258-480-4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 258-480-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 258-480-4 Use and application,EINECS 258-480-4 technical grade,usp/ep/jp grade.

Related News: If the government does not close the border and heed their other demands by 9 p.m., union members handling emergency services would also strike, the union said. DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT manufacturer If the government does not close the border and heed their other demands by 9 p.m., union members handling emergency services would also strike, the union said. DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT supplier However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT vendor However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. DANSYL-L-ASPARTIC ACID DI(CYCLOHEXYLAMMONIUM) SALT factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.